Although, based on the IgA tTG assays, a European study showed excess mortality risk particularly due to cancer among individuals with elevated IgA anti-tTG antibodies over 10 years’ follow-up period [18], no such study has been performed in a nationwide sample of the United States with systematical approaches. The gene discussed is CD79A; the disease is cancer.